New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
06:49 EDTACADACADIA option implied volatility is elevated
ACADIA option implied volatility is elevated, near the upper end of its 52-week range according to iVolatility.
News For ACAD From The Last 14 Days
Check below for free stories on ACAD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
09:01 EDTACADACADIA says FDA provisionally accepts trade name Nuplasid for pimavanserin
ACADIA Pharmaceuticals announced that the U.S. Food and Drug Administration has provisionally accepted the trade name “NUPLAZID” for pimavanserin. NUPLAZID is a selective serotonin inverse agonist and, if approved, will represent the first in a new class of drugs to treat psychosis. NUPLAZID has successfully completed a pivotal Phase III trial in Parkinson’s disease psychosis, which the FDA has agreed can serve as the basis, together with supportive data from other studies, for a New Drug Application. ACADIA plans to submit the NUPLAZID NDA to the FDA near the end of this year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use